secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2025-05-27T23:59:59+00:00
Accession:  0001437749-25-018482
Event type: other
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Cassava shareholders reject board declassification; director pay raised
-----------------------------------------------------------------------

- Proposal to reduce board classification from 3 to 2 classes failed despite 91% of votes cast in favor, lacking 66 2/3% of outstanding shares.
- Non-employee director annual cash retainer increased from $10,000 to $40,000; Board Chair gets additional $30,000.
- Annual stock option grant for continuing directors raised from 10,000 to 26,500 shares; initial grants rise to 53,000.
- Audit, Compensation, and Nominating Committee chairs receive $15,000, $10,000, and $8,000 annual cash fees respectively.
- Two directors elected: Robert Anderson, Jr. (5.64M for) and Michael J. O'Donnell (4.54M for) to three-year terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000143774925018482/0001437749-25-018482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000143774925018482/sava20250523_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-018482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer